CoChat

Current use of benzodiazepines in anxiety disorders

Cloos, Jean-Marc, Ferreira, Valérie · 2009 · Current Opinion in Psychiatry

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: The aim of this study is to provide a review of articles published between July 2007 and August 2008 on the current use and rationale of benzodiazepines in anxiety disorders. RECENT FINDINGS: Recent review articles confirm selective serotonin reuptake inhibitors as first-choice drugs for treating anxiety disorders, alongside newer agents such as pregabalin or serotonin-norepinephrine reuptake inhibitors, and combined with cognitive-behavioural therapy. Benzodiazepines are still widely used by clinicians for these disorders, as shown by recent surveys, even though their anxiolytic effectiveness is questioned. Newer agents are in development and may in the future resolve the therapeutic dilemma. SUMMARY: Despite current guidelines, benzodiazepines are still considered by many clinicians to remain good treatment options, in both the acute and the chronic phase of the treatment of anxiety disorders, partially because of their rapid onset of action and their efficacy with a favourable side effect profile, and also because of the sometimes only incomplete therapeutic response and the emergence of side effects of alternative medications. Having experienced good initial symptom relief with benzodiazepine treatment, patients may also be reluctant to taper it down. Clinicians should, however, bear in mind the frequent physiological dependence associated with these substances, and suggest both pharmacological and psychological treatment alternatives before opting for a long-term benzodiazepine treatment, which may remain necessary in certain clinical conditions.

Overview

Integrity signals

Registry

Crossref · 10.1097/yco.0b013e32831a473d

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 5

  1. Dailly, 2008, Pak J Pharm Sci, 21, 144
  2. Sim, 2007, Aust Fam Physician, 36, 923
  3. Chen, 2008, IDrugs, 11, 189
  4. Cortés-Cortés, 2007, Proc West Pharmacol Soc, 50, 87
  5. Atack, 2008, CNS Neurosci Ther, 14, 25, 10.1111/j.1755-5949.2007.00034.x · doi:10.1111/j.1755-5949.2007.00034.x · Paper page

Cited by

See all 127

Metadata

Authors
Cloos, J.-M., & Ferreira, V.
Corresponding author
Cloos, Jean-Marc
Venue
Current Opinion in Psychiatry
Published
2009-01
Volume
22
Issue
1
Pages
90-95
ISSN
0951-7367 (ISSN-L)
OpenAlex
W1971911881
Cited by
127
References
30
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 10 · 2019: 9 · 2018: 5 · 2017: 9 · 2016: 8 · 2015: 3 · 2014: 8 · 2013: 7 · 2012: 14
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
benzodiazepines, anxiety disorders, anxiolytic treatment, selective serotonin reuptake inhibitors, pregabalin, serotonin-norepinephrine reuptake inhibitors, cognitive behavioral therapy, benzodiazepine dependence, long-term benzodiazepine use
MeSH terms
Antidepressive Agents, Anxiety Disorders, Benzodiazepines, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current use of benzodiazepines in anxiety disorders. https://app.cochat.ai/papers/10.1097/yco.0b013e32831a473d
The paper
Cloos, J.-M., & Ferreira, V. (2009). Current use of benzodiazepines in anxiety disorders. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e32831a473d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.